We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

102 hedge funds and large institutions have $311M invested in iShares US Pharmaceuticals ETF in 2014 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 30 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

425% more first-time investments, than exits

New positions opened: 21 | Existing positions closed: 4

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

20% more capital invested

Capital invested by funds: $259M → $311M (+$52.1M)

19% more funds holding

Funds holding: 86102 (+16)

6.69% more ownership

Funds ownership: 105.34%112.03% (+6.7%)

3% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 30

Holders
102
Holders Change
+16
Holders Change %
+18.6%
% of All Funds
2.72%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
21
Increased
31
Reduced
30
Closed
4
Calls
Puts
Net Calls
Net Calls Change

IHE Hedge Fund Activity: Q4 2014 in Review

102 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q4 2014, worth a combined $311M — up 20% from $259M a quarter earlier.

Buyers outnumbered sellers: 21 funds opened new IHE positions and 4 closed out — a net gain of 17 holders — while 31 added to existing stakes and 30 trimmed.

The largest buyer was Brookstone Capital Management, opening a new position worth an estimated $15.1M. The largest seller was Bank of Montreal, cutting an estimated $12.1M.

  • 102 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q4 2014, up from 86 in Q3 2014.
  • Funds reported $311M of iShares US Pharmaceuticals ETF stock for Q4 2014, up 20% quarter-over-quarter.
  • 21 funds opened new iShares US Pharmaceuticals ETF positions in Q4 2014 and 4 closed out, a net change of +17 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q4 2014 was Brookstone Capital Management, an estimated $15.1M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q4 2014 was Bank of Montreal, an estimated $12.1M sold.

Based on aggregated 13F filings for Q4 2014.